How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/proteus-mirabilis-osteomyelitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Proteus Mirabilis Osteomyelitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proteus Mirabilis Osteomyelitis (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Proteus Mirabilis Osteomyelitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Tobi	tobramycin	Novartis		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Nebcin	Nebcin	University Hospital, Lille		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Proteus Mirabilis Osteomyelitis
Bristol-Myers Squibb · 1 drug in Proteus Mirabilis Osteomyelitis
Centre Hospitalier Universitaire Vaudois · 1 drug in Proteus Mirabilis Osteomyelitis
Generic (originally Roche) · 1 drug in Proteus Mirabilis Osteomyelitis
Novartis · 1 drug in Proteus Mirabilis Osteomyelitis
Pfizer · 1 drug in Proteus Mirabilis Osteomyelitis
Sterimax · 1 drug in Proteus Mirabilis Osteomyelitis
University Hospital, Lille · 1 drug in Proteus Mirabilis Osteomyelitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Proteus Mirabilis Osteomyelitis:

Cite this brief

Drug Landscape (2026). Proteus Mirabilis Osteomyelitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/proteus-mirabilis-osteomyelitis. Accessed 2026-06-10.

Proteus Mirabilis Osteomyelitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing